LianBio snags $325M IPO, slightly bigger than the multi-partnered biotech’s 2020 series A
The $300-plus million club is looking a little rarer this autumn in the biopharma arena, but LianBio looks to be one in less than a dozen to haul in at least that much in its Nasdaq debut Monday.